Submitted by Jos? Henrique Henrique (jose.neves@ufvjm.edu.br) on 2017-09-12T18:28:33Z No. of bitstreams: 2 license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) aline_bacelar_goncalves.pdf: 5988024 bytes, checksum: 24d09b3ca0a2e58cc7aee0ca7ca2528f (MD5) / Approved for entry into archive by Rodrigo Martins Cruz (rodrigo.cruz@ufvjm.edu.br) on 2017-09-18T12:57:54Z (GMT) No. of bitstreams: 2 license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) aline_bacelar_goncalves.pdf: 5988024 bytes, checksum: 24d09b3ca0a2e58cc7aee0ca7ca2528f (MD5) / Made available in DSpace on 2017-09-18T12:57:54Z (GMT). No. of bitstreams: 2 license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) aline_bacelar_goncalves.pdf: 5988024 bytes, checksum: 24d09b3ca0a2e58cc7aee0ca7ca2528f (MD5) Previous issue date: 2017 / Coordena??o de Aperfei?oamento de Pessoal de N?vel Superior (CAPES) / O tratamento das leucemias ? desafiador por v?rios aspectos, entre os quais podem ser destacados os efeitos adversos e a obten??o de op??es terap?uticas de alta qualidade e de custos razo?veis. A utiliza??o da enzima L-asparaginase como agente terap?utico, limita a fonte ex?gena de asparagina, da qual as c?lulas malignas dependem para o metabolismo celular e para a sobreviv?ncia. Essa ? uma op??o que oferece menores riscos ao paciente e ?s c?lulas sadias, que s?o capazes de sintetizar este amino?cido. Neste cen?rio o objetivo deste trabalho foi selecionar, entre fungos filamentosos, linhagens produtoras da enzima L-asparaginase. O estudo tamb?m buscou avaliar o efeito da varia??o da fonte de carbono e da raz?o carbono-nitrog?nio no crescimento e na express?o da atividade enzim?tica, a fim de desenvolver meios de cultivo para o processo produtivo. Realizou-se tamb?m um estudo do crescimento apical das tr?s linhagens selecionadas, duas do g?nero Penicillium sp. e uma do g?nero Fusarium sp., em diversos meios de cultivo. O conhecimento gerado sobre as linhagens produtoras e os demais estudos realizados permitiram a obten??o de um meio de cultivo que possibilitou a produ??o enzim?tica em at? 11,45 U.min-1.mL-1 com a linhagem de Fusarium sp. / Disserta??o (Mestrado) ? Programa de P?s-gradua??o em Ci?ncias Farmac?uticas, Universidade Federal dos Vales do Jequitinhonha e Mucuri, 2016. / The treatment of leukemia is challenging in many ways, including the adverse effects and obtaining treatment options of high quality and reasonable cost. The use of L-asparaginase enzyme as a therapeutic agent limits the exogenous source of asparagine, which the malignant cells depend for cellular metabolism and survival. This option offers lower risk to patients and healthy cells, which are able to synthesize this amino acid. Therefore, the objective of this work was to select among filamentous fungi, producing strains of L-asparaginase enzyme. The study also aimed at evaluating the effect of varying the carbon source and carbon-nitrogen ratio in the growth and expression of the enzymatic activity to develop culture media for the production process. It was also carried out a study of the apical growth of the three strains selected, two of the genus Penicillium sp. and one Fusarium sp., cultivated in various culture media. The knowledge about the growth of the strains studied in different nutritional sources and other studies allowed obtaining a culture medium that enabled the enzyme production of 11.45 U.min-1.mL-1 by Fusarium sp.

Made available in DSpace on 2016-04-04T12:26:00Z (GMT). No. of bitstreams: 2 14.pdf: 930696 bytes, checksum: 4334fa07716ed0ea4227a0d296d9310c (MD5) license.txt: 1748 bytes, checksum: 8a4605be74aa9ea9d79846c1fba20a33 (MD5) Previous issue date: 2015 / Fundação Oswaldo Cruz. Instituto de Tecnologia em Fármacos/Farmanguinhos. Rio de Janeiro, RJ, Brasil. / A asparaginase de origem bacteriana é o principal medicamento para o tratamento da leucemia linfoblástica aguda, um câncer que afeta principalmente as crianças. Apesar de efetivo, o medicamento causa sérias reações imunológicas por ser produzido por um procarioto. Atualmente, o medicamento existente no mercado brasileiro é importado, o que acarreta dependência tecnológica, alto custo na obtenção do medicamento e dificuldade de abastecimento. As asparaginase II de Saccharomyces cerevisiae codificada pelo gene ASP3 apresenta, por suas características, potencial para uso como medicamento antileucêmico. Em trabalhos anteriores, este gene foi clonado e expresso em altos níveis na levedura Pichia pastoris. O presente trabalho teve como objetivo caracterizar as propriedades físico-químicas e bioquímicas da asparaginase periplásmica recombinante produzida por P. pastoris, tendo sido avaliados as melhores condições de estocagem da enzima após ressuspensão, o efeito de alguns íons e de alguns compostos na atividade asparaginásica, a afinidade da asparaginase pelos substratos D e L-asparagina e L-glutamina e os seus parâmetros cinéticos. Observou-se que a ressuspensão da asparaginase de levedura em água destilada e mantida a 4 °C reteve em torno de 98% da atividade original após 96 horas, na presença de sorbitol 0,1 M, mostrando ser esta a melhor condição de estocagem. Os valores do Km e da Vmáx foram determinados, obtendo-se 2,461 ± 0,170mM e 0,090 ± 0,0017mM min-1, respectivamente. A asparaginase de P.pastoris recombinante apresentou maior afinidade pela D-asparagina, de forma semelhante à asparaginase nativa de S. cerevisiae; e baixa atividade glutaminásica, o que favorece a sua utilização como medicamento pelo menor risco de efeitos tóxicos. O EDTA não apresentou efeito negativo sobre a asparaginase de levedura, indicando não ser a mesma uma metaloenzima. A influência negativa de agentes redutores sobre a atividade enzimática indica a presença de pontes de enxofre na estrutura proteica. Os resultados obtidos são de extrema importância para a continuidade dos estudos da utilização da asparaginase de Pichia pastoris recombinante como agente antileucêmico. / Bacterial asparaginase is the main medicament for the treatment of acute lymphoblastic leukemia, a cancer that primarily affects children. Although effective, the medicine causes serious immunological reactions due to its prokaryotic origin. Currently, the existing drug in the Brazilian market is imported, which carries a technological dependence, high cost and supply difficulties. The asparaginase II of Saccharomyces cerevisiae encoded by the ASP3 gene, given its characteristics, has potential to be used as an antileukemic drug. In previous work, this gene was cloned and expressed at high levels in the yeast Pichia pastoris. The present work aimed to characterize the physicochemical and biochemical properties of the recombinant periplasmic asparaginase produced by P. pastoris, having been assessed the best enzyme storage conditions after resuspension, the effect of some ions and some compounds in asparaginasic activity, asparaginase affinity for yhe substrates D- and L-asparagine and Lglutamine and its kinetic parameters. It was observed that the yeast asparaginase resuspension in distilled water and kept at 4 °C retained about 98% of the original activity after 96 hours in the presence of 0.1 M sorbitol, showing this to be the best storage condition. The values of Km and Vmax were determined to be 2,461 ± 0,170mM e 0,090 ± 0,0017mM min-1, respectively. The recombinant asparaginase showed higher affinity for D-asparagine, similarly to the native S. cerevisiae asparaginase; and low glutaminasic activity, which favors its use as a medicine due to the lower risk of toxic effects. EDTA showed no negative effect on the yeast asparaginase, indicating that it is not a metalloenzyme. The negative influence of reducing agents on the enzymatic activity indicates the presence of sulfur bridges in the protein structure. These results are extremely important for the further studies on the use of the recombinant Pichia pastoris asparaginase as antileukemic agent.

Malgré l'amélioration des traitements, environ 20% des patients atteints de leucémie aigue lymphoblastiques (LAL) rechutent dans la moelle osseuse ou dans des sites extra-médullaires tels que les ovaires et les testicules, ce qui est particulièrement fréquent dans les rechutes tardives de LAL-B présentant un remaniement ETV6/RUNX1. Les travaux réalisés par Virginie Gandemer en 2007, ont montré que l'expression de CD9 permettait de distinguer les leucémies ETV6/RUNX1 des autres types de leucémie. Le gène CD9 code pour une protéine de la famille des tétraspanines dont l'expression a été corrélée avec le risque métastatique et la survie des patients. Par ailleurs il a été démontré que la protéine CD9 était impliquée dans le homing et la prise de greffe des cellules souches hématopoïétiques et leucémiques. Nous avons donc émis l'hypothèse qu'à travers ses propriétés fonctionnelles sur la migration et le homing, CD9 pourrait être un acteur clé des rechutes de LAL-B. Le but de ce travail de thèse était donc premièrement de déterminer le mode de régulation de CD9 dans les LAL-B ETV6/RUNX1 et deuxièmement de déterminer les effets de l'expression de CD9 sur la motilité et la prise de greffe des LAL-B. Les analyses préalablement réalisées au laboratoire avaient suggéré que CD9 pouvait être régulé par des miARNs. Nous avons identifié un cluster de 3 miARNs potentiellement impliqués dans la régulation de CD9 dans les LAL-B ETV6/RUNX1. Ces résultats doivent cependant être complétés par d'autres analyses fonctionnellles afin d'être confirmés. Nous avons étudié le rôle de la protéine CD9 dans la dissémination des cellules de LAL-B. Nous avons démontré que CD9 était un régulateur potentiel de l'adhésion et un nouveau facteur impliqué dans la migration et le homing dépendants de CXCR4 en favorisant l'activation de RAC1 et les réarrangements de l'actine en réponse au CXCL12. Enfin, nous avons décrit pour la première fois l'influence de CD9 sur la migration et le homing dans les testicules via RAC1. Nos résultats montrent donc que CD9 favorise la dissémination des cellules de LAL-B dans les testicules et suggèrent que cette protéine pourrait constituer un acteur majeur des rechutes tardives de LAL-B dont les mécanismes d'apparitions sont peu connus. / Despite improvements in survival rates, approximately 20% of children suffering from acute lymphoblastic leukemia (B-ALL) present relapses from bone marrow or from B-extramedullary sites, such as the testes or ovaries, particularly in cases of late relapse of ETV6/RUNX1-ALL. Virgine Gandemer showed in 2007, that the expression of CD9, a protein from the tetraspanin superfamily, can be used to distinguish ETV6/RUNX1 lymphoblastic leukemia from other types of ALL. CD9 expression has been correlated with the risk of metastasis and is associated with a poor clinical outcome in various types of cancer. Moreover CD9 has been implicated in hematopoietic and leukemic stem cell homing. We hypothesized, that CD9 protein, through its functional properties on migration and homing, could be a key actor of B-ALL relapses. The purpose of our study was then to investigate, first the transcriptional regulation of CD9 in ETV6/RUNX1 B-ALL and secondly, the effect of CD9 expression on motility and engrafment of B lymphoblasts. The analysis of CD9 transcriptional regulation previously made in the team, suggested that it could be regulated by miRNAs. We identified a cluster of 3 miRNAs potentially implicated in the regulation of CD9 expression in ETV6/RUNX1 B-ALL. This result has to be confirmd by more functional analysis. We investigated the role of CD9 in the dissemination of B-ALL. We identified CD9 as a potential regulator of B-ALL cell adhesion and a new factor involved in CXCR4-mediated migration and homing, through the promotion of actin rearrangement in response to CXCL12. We also characterized the effect of CD9 protein expression on RAC1 activation, which had an impact on blast migration and engraftment. Finally, we described, for the first time, the influence of CD9, mediated by RAC1 signaling, on B-cell chemotactic migration and homing in the testis. Our work provides evidence for an impact of CD9 on the ability of pre-B leukemic cells to disseminate to testes, through its effects on migration and homing, and suggests that CD9 may be a key player in late relapses of B-ALL, which are currently poorly understood.

Introduction: The Central Nervous System (CNS) is an important site of relapse in patients with Acute Lymphoblastic Leukemia (ALL), despite increasing cure rates in the last four decades in young patients. The presence of leukemic blasts in the Cerebrospinal Fluid (CSF) presents prognostic implication and therefore defines changes in the therapeutic protocol, which is why it requires diagnostic accuracy. The emergence of new techniques for identifying CSF leukemia blasts, such as flow cytometry and molecular methods, which are more costly and not uniformly accessible for clinical use, have led to the need to reassess the role of conventional cytology as diagnostic tool. Objectives: To identify the proportion of CSF samples positive for blasts in children and adolescents with ALL, using a standardized cytology technique and with standardization of variables related to the process that could interfere with the result. DESIGN: Prospective, descriptive, uncontrolled study in which samples of CSF obtained by lumbar puncture of patients with ALL that were starting treatment were examined. CSF samples were sent to the laboratory shortly after collection, being processed and cytocentrifugated in cytofunyl in up to four hours after collection. Four slides were prepared, stained and analyzed by a pathologist and a hematologist. RESULTS: Twenty-eight patients with ALL were evaluated, with predominance of male (58.6%), immunophenotype B (82.2%) and 78.5% were stratified as high risk for relapse. Of the 205 CSF samples evaluated, 26 (12.6%) were positive for blasts and among 28 patients, 11 (39.2%) had CSF with neoplastic infiltration. Comparing the groups with and without CNS infiltration, no statistically significant difference was observed for the variables analyzed. CONCLUSIONS: Conventional cytology was effective in the identification of CNS infiltration by blasts, provided there is a vigilance of factors related to collection, processing and analysis of CSF that may interfere in the reliability of the result. / Introdução: O Sistema Nervoso Central (SNC) é importante sítio de recaída em pacientes com Leucemia Linfoblástica Aguda (LLA), apesar das crescentes taxas de cura nas últimas quatro décadas em pacientes jovens. A presença de blastos leucêmicos no Líquido Cefalorraquiano (LCR) apresenta implicação prognóstica e, portanto, define mudanças no protocolo terapêutico, razão pela qual requer acurácia diagnóstica. O surgimento de novas técnicas de identificação de blastos leucêmicos no LCR, como a citometria de fluxo e os métodos moleculares, que têm custo mais elevado e não estão uniformemente acessíveis para uso clínico, trouxe a necessidade de reavaliar-se o papel da citologia convencional como instrumento diagnóstico. Objetivos: Identificar a proporção de exames de LCR positivos para blastos em crianças e adolescentes com LLA, utilizando-se de técnica de citologia padronizada e com padronização de variáveis relacionadas ao processo que pudessem interferir no resultado. Delineamento: Estudo prospectivo, descritivo, não controlado, no qual foram examinadas amostras de LCR obtidas por punção lombar de pacientes com LLA que estavam iniciando o tratamento. As amostras de LCR foram encaminhadas ao laboratório logo após a coleta, sendo processadas e citocentrifugadas em citofunil em até no máximo quatro horas após a coleta. Quatro lâminas foram preparadas, coradas e analisadas por um patologista e um hematologista. Resultados: Foram avaliados 28 pacientes com LLA, havendo predomínio do sexo masculino (58,6%), imunofenótipo B (82,2%) e 78,5% foram estratificados como de alto risco para recaída. Dentre as 205 amostras de LCR avaliadas, 26 (12,6%) foram positivas para blastos e dentre os 28 pacientes, 11 (39,2%) obtiveram algum exame de LCR com infiltração neoplásica. Comparando-se os grupos com e sem infiltração de SNC, não se observou diferença estatisticamente significante para as variáveis analisadas. Conclusão: Citologia convencional foi efetiva na identificação de infiltração de SNC por blastos leucêmicos, desde que haja vigilância dos fatores relacionados a coleta, processamento e análise do LCR que possam interferir na fidedignidade do resultado. / Aracaju, SE

Este estudo teve como objetivo avaliar o estado nutricional relativo ao selênio (Se) de pacientes na fase de pós-tratamento da leucemia linfóide aguda (LLA) e sua relação com o estresse oxidativo. Foram selecionados 24 pacientes no pós-tratamento da LLA (9,2 ± 1,9 anos) atendidos no Instituto de Oncologia Pediátrica da Universidade Federal de São Paulo e 60 indivíduos saudáveis (9,5 ± 1,3 anos) da Escola de Aplicação da Universidade de São Paulo. Foram coletados 10 mL de sangue venoso para análise de Se plasmático e eritrocitário, glutationa peroxidase (GPx), superóxido dismutase (SOD), α- tocoferol, malondialdeído (MDA) e 8-oxo-desoxiguanosina (8-oxo-dGuo). A urina de 24 horas foi coletada para análise da excreção de Se, e três recordatórios de consumo alimentar de 24 horas para avaliação do Se ingerido. Os resultados obtidos quanto aos parâmetros bioquímicos de avaliação de Se não apresentaram diferença significativa entre os grupos de pacientes e controles, e foram respectivamente: Se plasmático, 44,4 ± 9,0 µg/L e 48,7 ± 12,0 µg/L (p = 0,122); Se eritrocitário, 49,9 ± 15,9 µg/L e 45,0 ± 15,9 µg/L (p = 0,202); Se urinário, 19,6 ± 14,8 µg Se/g de creatinina e 18,6 ± 9,6 µg Se/g de creatinina (p = 0,820). O consumo médio de Se foi de 27,4 ± 8,7 µg/dia e 28,0 ± 1,5 µg/dia (p = 0,756), respectivamente. Os grupos estudados foram considerados deficientes em Se, considerando os pontos de corte adotados. A atividade da GPx foi significativamente menor nos pacientes do que nos controles (33,3 ± 11,1 U/g Hb e 76,9 ± 25,9 U/g Hb) (p = 0,000), e a atividade da SOD não diferiu entre pacientes e controles (1796,9 ± 257,8 U/g Hb e 1915,9 ± 473,9 U/g Hb) (p = 0,145), assim como as concentrações de MDA (1,7 ± 0,3 µmol/L e 1,8 ± 0,4 µmol/L) (p = 0,053). A concentração de α-tocoferol foi estatisticamente maior nos pacientes que nos controles (17,7 ± 4,7 µmol/L e 10,6 ± 3,2 µmol/L) (p =0,000), bem como a concentração de 8-oxo-dGuo (43,6 ± 28,0 8-oxo/106 dG e 21,3 ± 22,9 8-oxo/106 dG) (p = 0,014). Os resultados apresentados apontam que os participantes deste estudo estão deficientes em Se e, em especial os pacientes no pós-tratamento da LLA estão sujeitos a um aumento do estado de estresse oxidativo, pois apesar das concentrações de MDA serem semelhantes entre os pacientes e os controles, a atividade da GPx dos pacientes foi reduzida e a concentração de 8-oxo-dGuo e α-tocoferol estavam aumentadas em relação aos controles. / This study aimed to evaluate the nutritional status of selenium (Se) in patients in post-treatment of acute lymphoblastic leukemia (ALL) and its relationship with oxidative stress. We selected 24 patients in post-treatment of ALL (9.2 ± 1.9 years) at the Pediatric Oncology Institute of Federal University of São Paulo and 60 healthy individuals (9.5 ± 1.3 years) of the School of Application at the University of São Paulo. We collected 10 mL of venous blood for analysis of Se in plasma and erythrocytes, glutathione peroxidase (GPx), superoxide dismutase (SOD), α-tocopherol, malondialdehyde (MDA) and 8-oxo-deoxyguanosine (8-oxo-dGuo). The 24-hour urine was collected for analysis of Se excretion and Se intake was evaluated by using three non-consecutive days of 24- hour recall. The results regarding biochemical evaluation of Se did not differ significantly between patients in post-treatment of ALL and controls, and the results were respectively: Se in plasma, 44.4 ± 9.0 µg/L and 48.7 ± 12.0 µg/L (p = 0.122); Se in erythrocytes, 49.9 ± 15.9 µg/L and 45.0 ± 15.9 µg/L (p = 0.202); Se in urine, 19.6 ± 14.8 µg Se/g creatinine and 18.6 ± 9.6 µg Se/g creatinine (p = 0.820). The average intake of selenium was 27.4 ± 8.7 mg/day and 28.0 ± 1.5 mg/day (p = 0.756), respectively. Both groups were considered deficient in selenium, according to the cut-off points adopted. The GPx activity was significantly lower in patients than in controls (33.3 ± 11.1 U/g Hb and 76.9 ± 25.9 U/g Hb) (p = 0.000), and no difference in SOD activity was observed between groups (1796.9 ± 257.8 U/g Hb and 1915.9 ± 473.9 U/g Hb) (p = 0.145). MDA concentrations were not different between patients and controls (1.7 ± 0.3 µmol/L and 1.8 ± 0.4 µmol/L) (p = 0.053) and α-tocopherol concentration was statistically higher in patients (17.7 ± 4.7 µmol/L and 10.6 ± 3.2 µmol/L) (p = 0.000), as well the concentration of 8-oxo-dGuo (43.6 ± 28.0 8-oxo/106 dG and 21.3 ± 22.9 8-oxo/106 dG) (p = 0.014). These results indicate that the participants in this study are deficient in Se mainly those who are in post-treatment of ALL are exposed to an increased state of oxidative stress, because although the concentrations of MDA were similar between patients and controls, the GPx activity of the patients was reduced and the concentration of 8-oxo-dGuo and α-tocopherol were increased compared to controls.

Orientador: José Andres Yunes / Tese (doutorado) - Universidade Estadual de Campinas, Instituto de Biologia / Made available in DSpace on 2018-08-21T05:50:44Z (GMT). No. of bitstreams: 1 Jotta_PatriciaYoshioka_D.pdf: 8922035 bytes, checksum: 3734371a320410ba431d6e6ce6579e55 (MD5) Previous issue date: 2012 / Resumo: A leucemia linfóide aguda (LLA) é o câncer mais frequente na infância, e destas, 15% são do tipo T (LLA-T). A hiperativação da via PI3K/Akt tem sido amplamente descrita em tumores e em linhagens celulares de LLA-T. PTEN é o principal regulador negativo dessa via e frequentemente encontra-se inativado em cânceres humanos. Com frequência, pacientes com LLA-T apresentam mutações ativadoras de NOTCH1. NOTCH1 pode regular transcricionalmente PTEN, contudo ainda não está claro como as mutações ativadoras de NOTCH1 influenciariam a expressão de PTEN nas LLA-T. Nós encontramos uma ocorrência de 11 (17,7%) mutações no éxon 7 do PTEN em 62 casos de LLA-T estudados consecutivamente. Contudo, nenhuma mutação foi encontrada na análise de 71 casos de LLA-B derivada. A maioria das mutações de PTEN apresentavam inserções/deleções de mais de 3 nucleotídeos. Não encontramos associação entre mutações em PTEN e o gênero, a idade e a contagem de glóbulos brancos ao diagnóstico. Pacientes com alterações no PTEN apresentaram uma tendência a pior sobrevida global (OS, p=0.07). Dentre os pacientes de LLA-T classificados como alto risco (n=56), aqueles possuindo anormalidades no PTEN mostraram-se associados significativamente a menor OS (p=0.019) e sobrevida livre de leucemia (LFS 47% vs 76%; p=0.045). As curvas de LFS foram significativamente diferentes (p=0.003), mesmo considerando apenas pacientes que atingiram a remissão no dia 28 do tratamento para a análise. Nosso estudo também mostrou que pacientes com mutações em NOTCH1 apresentavam aumento na transcrição de MYC e menor expressão de PTEN mRNA comparados a pacientes com NOTCH1 selvagem. Nós recentemente demonstramos que células de LLA-T apresentavam fosforilação de PTEN mediada por CK2, resultando na estabilização e consequentemente inativação da proteína PTEN. Corroborando ao estudo anterior, os casos de LLA-T analisados, independente do status de mutação em NOTCH1, expressam níveis significativamente mais altos de proteína PTEN do que controles normais. Para avaliar o impacto da regulação transcricional de NOTCH e a inativação postranscricional por CK2 de PTEN, nós tratamos as células de LLA-T com inibidores de gamma-secretase (DAPT e de CK2 (DRB/TBB). Nosso estudo enfatiza a relevância biológica e clínica da regulação do PTEN em LLA-T. E sugerimos o uso combinado de inibidores de gamma-secretase e CK2 devem possuir potencial terapêutico nas LLA-T / Abstract: T-cell acute lymphoblastic leukemia (T-ALL) accounts for approximately 15% of pediatric ALL. Patients with T-ALL are at increased risk of relapse compared with children treated for B-cell precursor ALL. Mutations in the phosphatase and tensin homolog (PTEN) gene leading to PTEN protein deletion and subsequent activation of the PI3K/Akt signaling pathway are common in cancer. PTEN is the main negative regulator of the PI3K/Akt survival pathway. T-ALL patients frequently display NOTCH1 activating mutations and Notch can transcriptionally down-regulate the tumor suppressor PTEN. However, it is not clear whether NOTCH1 mutations associate with decreased PTEN expression in primary T-ALL. We report that PTEN exon 7 mutations occurred in 11 (17.7%) out of 62 consecutive pediatric T-cell acute lymphoblastic leukemia (T-ALL) but in none of 71 precursor B-ALL patients. Most PTEN mutations were insertions/deletions of more than 3 nucleotides. No associations were found between PTEN mutation and age, gender, WBC at diagnosis, early response to therapy and remission rate. Patients with PTEN mutation (n=11) had a tendency toward worse overall survival (OS, p=0.07). Remarkably, PTEN mutations were significantly associated with lower OS (p=0.019) and leukemia-free survival (LFS 47% vs 76%, p=0.045) within patients classified in the high risk group (n=56). LFS curves were significantly different (p=0.003) even if only patients who reached remission on day 28 were considered for analysis. We compared patients with or without NOTCH1mutations and report that the former presented higher MYC transcript levels and decreased PTEN mRNA expression. We recently showed that T-ALL cells frequently display CK2-mediated PTEN phosphorylation, resulting in PTEN protein stabilization and concomitant functional inactivation. Accordingly, the T-ALL samples analyzed, irrespectively of their NOTCH1 mutational status, expressed significantly higher PTEN protein levels than normal controls. To evaluate the integrated functional impact of NOTCH transcriptional and CK2 post-translational inactivation of PTEN, we treated TALL cells with both the gamma-secretase inhibitor DAPT and the CK2 inhibitors DRB/TBB. Our data suggest that combined use of gamma-secretase and CK2 inhibitors may have therapeutic potential in T-ALL. And emphasize the biological and clinical relevance of PTEN regulation in pediatric T-ALL / Doutorado / Genetica Animal e Evolução / Doutor em Genetica e Biologia Molecular

Orientador: José Andrés Yunes / Tese (doutorado) - Universidade Estadual de Campinas, Instituto de Biologia / Made available in DSpace on 2018-08-20T10:04:03Z (GMT). No. of bitstreams: 1 Laranjeira_AngeloBrunelliAlbertoni_D.pdf: 13248620 bytes, checksum: 729ec8e23331934ddd1e5803361b6fe6 (MD5) Previous issue date: 2012 / Resumo: A Leucemia Linfóide Aguda (LLA) é o tipo de câncer mais comum que acomete crianças. Sabe-se que a interação do tumor com o contexto celular do hospedeiro (microambiente tumoral) é recíproca, ou seja, na medida em que o tumor estimula o seu microambiente, este potencializa a sobrevivência, proliferação e invasividade tumoral. A interação da LLA com as células estromais da medula óssea tem um impacto positivo na resistência das células leucêmicas à quimioterapia. No presente estudo foi investigado a modulação de uma série genes de sensibilidade e resistência à asparaginase em células de LLA-B precursoras após co-cultura com as células estromais. Mostramos o aumento da expressão e secreção da IGFBP7 pelas células leucêmicas após co-cultivo com células do estroma da medula óssea. Em ensaios com o silenciamento do IGFBP7 em células leucêmicas e células estromais, mostramos que a IGFBP7 atua regulando positivamente o crescimento celular e aumenta a resistência a asparaginase. A IGFBP7 'leucêmica' junto com IGF/insulina atua sobre as células estromais, induzindo nestas células o aumento da produção de asparagina, e diminuindo a ação da asparaginase. Além deste mecanismo de resistência dependente das células estromais, mostramos que a IGFBP7 em conjunto com IGF/insulina promove a resistência das células leucêmicas à ação de outros compostos quimioterápicos (dexametasona e metotrexato) de forma independente da interação leucemia-estroma. Ainda pode ser observado que o plasma de crianças com LLA ao diagnóstico, apresenta maiores níveis de IGFBP7 do que em amostras controles. É importante ressaltar que níveis mais altos de mRNA IGFBP7 foram associados com menor sobrevida livre de leucemia (Modelo de regressão de Cox, P = 0,003), em células de LLAB Ph(-) presursoras / Abstract: Acute Lymphoblastic Leukemia (ALL) is the most common type of cancer that affects children. It is known that the interaction between tumor and the cellular context of the host (tumor microenvironment) is reciprocal, ie, to the extent that the tumor stimulates their microenvironment, this enhances the survival, proliferation and tumor invasiveness. The interaction of ALL with bone marrow stromal cells has a positive impact on leukemia resistance to chemotherapy. In the present study, we investigated the modulation of a series of putative asparaginase-resistance/sensitivity genes in B-precursor ALL upon co-culture with stromal cells. We showed an increase expression and secretion of IGFBP7 in leukemic cells after co-culture with BMSCs. Assays with IGFBP7 knockdown in leukemic cells and stromal cells, showed that IGFBP7 acts as a positive regulator of cell growth and increases resistance to asparaginase. 'Leukemic' IGFBP7 together with IGF/insulin acts on stromal cells, increasing asparagine production, thus reducing the asparaginase effect. Besides this mechanism of resistance dependent of stromal cells, we showed that IGFBP7 in conjunction with IGF/insulin promotes the resistance of leukemia cells to the action of other chemotherapeutic compounds (dexamethasone and methotrexate) independently of the interaction leukemia-stroma. We still observed that diagnostic BM plasma from children with ALL at diagnosis, have higher levels of IGFBP7 than control samples. Importantly, higher levels of IGFBP7 mRNA were associated with lower leukemia-free survival (Cox regression model, P = 0.003) in precursor B-ALL Ph (-) patients / Doutorado / Genetica Animal e Evolução / Doutor em Genetica e Biologia Molecular

Males and age group 1 to 5 years show a much higher risk for childhood acute lymphoblastic leukemia (ALL). We performed a case-only genome-wide association study (GWAS), using the Illumina Infinium HumanCoreExome Chip, to unmask gender- and age-specific risk variants in 240 non-Hispanic white children with ALL recruited at Texas Children’s Cancer Center, Houston, Texas. Besides statistically most significant results, we also considered results that yielded the highest effect sizes. Existing experimental data and bioinformatic predictions were used to complement results, and to examine the biological significance of statistical results. Our study identified novel risk variants for childhood ALL. The SNP, rs4813720 (RASSF2), showed the statistically most significant gender-specific associations (P < 2 x 10-6). Likewise, rs10505918 (SOX5) yielded the lowest P value (P < 1 x 10-5) for age-specific associations, and also showed the statistically most significant association with age-at-onset (P < 1 x 10-4). Two SNPs, rs12722042 and 12722039, from the HLA-DQA1 region yielded the highest effect sizes (odds ratio (OR) = 15.7; P = 0.002) for gender-specific results, and the SNP, rs17109582 (OR = 12.5; P = 0.006), showed the highest effect size for age-specific results. Sex chromosome variants did not appear to be involved in gender-specific associations. The HLA-DQA1 SNPs belong to DQA1*01:07and confirmed previously reported male-specific association with DQA1*01:07. Twenty one of the SNPs identified as risk markers for gender- or age-specific associations were located in the transcription factor binding sites and 56 SNPs were non-synonymous variants, likely to alter protein function. Although bioinformatic analysis did not implicate a particular mechanism for gender- and age-specific associations, RASSF2 has an estrogen receptor-alpha binding site in its promoter. The unknown mechanisms may be due to lack of interest in gender- and age-specificity in associations. These results provide a foundation for further studies to examine the gender- and age-differential in childhood ALL risk. Following replication and mechanistic studies, risk factors for one gender or age group may have a potential to be used as biomarkers for targeted intervention for prevention and maybe also for treatment.

Orientador: José Andrés Yunes / Dissertação (mestrado) - Universidade Estadual de Campinas, Instituto de Biologia / Made available in DSpace on 2018-08-24T08:28:04Z (GMT). No. of bitstreams: 1 Milani_Mateus_M.pdf: 3959646 bytes, checksum: a36674e099fefbc487286cdc33006c0a (MD5) Previous issue date: 2014 / Resumo: A leucemia linfoide aguda (LLA) é o câncer mais comum na infância. O transplante de células primárias de LLA humana em camundongos imunosuprimidos tem sido de suma importância para o entendimento da fisiopatologia da doença e para o teste de novos fármacos. Ao contrário de modelos animais de tumores sólidos, cujo volume é facilmente medido na superfície dos animais, a LLA infiltra órgãos inacessíveis ao exterior, daí a necessidade de definir métodos adequados para o monitoramento da progressão da doença. Resultados aqui apresentados indicam que proteínas secretadas pela LLA podem servir como marcadores quantitativos da carga leucêmica, facilmente aferidos por ELISA de amostras de plasma sanguíneo. Dentre três proteínas testadas (B2M, IGFBP2 e Hsp90), o ELISA de Hsp90 apresentou sensibilidade superior à análise da porcentagem de células leucêmicas no sangue dos animais, por citometria de fluxo de células marcadas com anti-huCD45. Os níveis de Hsp90 humano no plasma sanguíneo mostraram-se positivamente correlacionados com o porcentual de células leucêmicas na medula óssea e fígado e em menor grau com os níveis do baço e sangue periférico (SP) ao longo do tempo, tanto nas LLA de linhagem B quanto nas LLA-T. O ELISA de Hsp90 permite detectar a instauração da leucemia nos animais transplantados, até duas semanas antes da detecção pelo método tradicional de análise de sangue periférico por citometria de fluxo. Ao contrário do observado para IGFBP2, o tratamento dos animais leucêmicos com Dexametasona ou um inibidor da PI3K não interferiu nos níveis de Hsp90, que se mantiveram proporcionais à porcentagem de células leucêmicas huCD45+ no sangue periférico. No conjunto, os resultados demonstram que a análise do plasma dos animais por ELISA de Hsp90 é um método melhor do que os atualmente utilizados, para diagnóstico precoce e acompanhamento de LLA humana quando em níveis de doença residual mínima, ou seja, quando a porcentagem de células de LLA é inferior a 5% do total de células da medula óssea / Abstract: Acute lymphoblastic leukemia (ALL) is the most common type of childhood cancer . The transplantation of human primary ALL cells in immunodeficient mice has been of much importance for understanding the disease's pathophysiology and testing new drugs. Unlike animal models of solid tumors whose volume is easily measured on the animal surface, the ALL infiltrates organs that are inaccessible to external antigens, hence the need to define more suitable methods for monitoring the disease's progression. Results presented here indicate that proteins secreted by the ALL can serve as quantitative markers of leukemic burden and are easily measured by ELISA of blood plasma samples. Among three tested proteins (B2M, IGFBP2 and Hsp90), Hsp90 ELISA analysis showed higher sensitivity than the analysis of leukemic cells on animal blood by flow cytometry of anti- huCD45 labeled cells. The levels of Hsp90 in human blood plasma were shown to be positively correlated with the percentage of leukemic cells in the bone marrow and liver and to a lesser extent with the levels in the spleen and peripheral blood (PB) over time, both in B-lineage ALL as in ALL-T. The Hsp90 ELISA allows the leukemia's engraftment detection in transplanted animals up to two weeks prior to detection by the traditional method of peripheral blood analysis by flow cytometry. Unlike observed for IGFBP2, treatment of leukemic animals with Dexamethasone or PI3K inhibitors did not interfere in Hsp90 levels, which remained proportional to the percentage of huCD45+ leukemic cells in the peripheral blood. Taken together, the results demonstrate that the analysis of animal plasma by Hsp90 ELISA is a better method than those currently used for early diagnosis and monitoring of human ALL on minimal residual disease levels, when the percentage of ALL cells is less than 5 % of the total bone marrow cells / Mestrado / Genetica Animal e Evolução / Mestre em Genética e Biologia Molecular

With the increase in survival for children with cancer, part of the focus of current research is aimed towards evaluating how these children are adapting psychosocially. Neurocognitive deficits have been well established. However, there are multiple facets encompassing quality of life, including general mental health, lifestyles and health behaviors, and academic and cognitive functioning. The relationship between neurocognitive and psychosocial functioning has yet to be thoroughly evaluated. The purpose of this study was to investigate the relationship between neurocognitive and psychosocial functioning in survivors of brain tumors and acute lymphoblastic leukemia. Data was collected from existing archival database comprised of patients of the at Cook Children's Medical Center in Texas. The sample consisted of 177 patients between the ages of 3 and 12 who were at least two years post-diagnosis. Measures used included the NEPSY and the Behavioral Assessment for Children. Statistical analyses included a several one-way analysis of variances, an independent samples t-test, a univariate analysis of variance, a hierarchical multiple regression, and odds ratio analyses. Results indicated survivors treated with neurosurgery alone appear to be less at risk for developing behavior problems than other treatment modalities. Also, brain tumor survivors demonstrate more problematic behaviors than survivors of acute lymphoblastic leukemia. Visuospatial functioning, diagnosis, and type of treatment were found to be predictive variables of behavior problems. Attention, and perhaps language, deficits may predispose children to more problems in their behavior. It is concluded that there are other factors affecting behavior in this population that were not accounted for in this analysis. It is recommended for future studies to research the individual clinical scales of the Behavior Assessment System for Children, obtain information from multiple informants, study this relationship longitudinally, and research additional factors that may be influencing the relationship between neurocognitive and psychosocial functioning. This provides evidence of risk factors that should be monitored as the child returns home and to school.